# Phase 2 sclerosis trials recruiting: 49 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials in phase 2 for sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 sclerosis trials: 49 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 49
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07840326 | A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) | Sundance Biosciences, Inc. | Phase 2 | Recruiting | Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS)... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840326) |
| September 22, 2026 | NCT07834450 | Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis | Huashan Hospital | Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834450) |
| September 22, 2026 | NCT07833618 | A Phase II Study of ALT001 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833618) |
| September 18, 2026 | NCT07827716 | A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Relapsing Remitting Multiple Sclerosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827716) |
| September 10, 2026 | NCT07813858 | Colchicine Effect on Amyotrophic Lateral Sclerosis Patients | Azienda Ospedaliero-Universitaria di Modena | Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813858) |
| August 20, 2026 | NCT07776743 | A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776743) |
| August 14, 2026 | NCT07765212 | Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Multiple Sclerosis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765212) |
| July 2, 2026 | NCT07680322 | Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) | Aeovian Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | Tuberous Sclerosis Complex, Epilepsy | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680322) |
| April 3, 2026 | NCT07510607 | Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Sclerosis, RRMS, Relapsing Remitting MS | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510607) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |
| March 27, 2026 | NCT07497399 | Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | Johns Hopkins University | Phase 2 | Recruiting | Multiple Sclerosis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497399) |
| March 12, 2026 | NCT07467746 | Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids | The Third Xiangya Hospital of Central South University | Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07467746) |
| December 30, 2025 | NCT07310914 | Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis | Danish Multiple Sclerosis Hospitals | Phase 2 | Not yet recruiting | Multiple Sclerosis | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310914) |
| December 19, 2025 | NCT07294144 | Tofersen in Non-SOD1 ALS | Washington University School of Medicine | Phase 2 | Recruiting | ALS (Amyotrophic Lateral Sclerosis) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294144) |
| December 4, 2025 | NCT07263607 | A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis | Sichuan Academy of Medical Sciences | Phase 2 | Not yet recruiting | Multiple Sclerosis (MS) Relapsing Remitting | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263607) |
| October 30, 2025 | NCT07222956 | A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS)... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222956) |
| August 26, 2025 | NCT07142291 | PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | PhenoNet, Inc. | Phase 2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07142291) |
| August 22, 2025 | NCT07138014 | FHND1002 for ALS Treatment: Phase 2 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138014) |
| July 17, 2025 | NCT07071935 | A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS) | University of Pennsylvania | Phase 2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure, Neuromuscular Disease Patients, Neuromuscular... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07071935) |
| June 17, 2025 | NCT07023835 | Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis | Zydus Therapeutics Inc. | Phase 2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07023835) |
| June 13, 2025 | NCT07020715 | A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis | University Hospital, Antwerp | Phase 2 | Not yet recruiting | Multiple Sclerosis | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020715) |
| June 3, 2025 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Reunion Neuroscience Inc | Phase 2 | Recruiting | Adjustment Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07002034) |
| May 7, 2025 | NCT06961383 | Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis | NeuroGenesis Ltd. | Phase 2 | Not yet recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961383) |
| May 4, 2025 | NCT06956326 | Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Sclerosis | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956326) |
| March 30, 2025 | NCT06901687 | Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) | NYU Langone Health | Phase 2 | Recruiting | Multiple Sclerosis, Depression | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06901687) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Johns Hopkins University | 2 |
| The Third Xiangya Hospital of Central South University | 1 |
| University of California, San Francisco | 1 |
| Zydus Therapeutics Inc. | 1 |
| [TG Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc) | 1 |
| PhenoNet, Inc. | 1 |
| Aeovian Pharmaceuticals, Inc. | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| University of Kansas Medical Center | 1 |
| Casa Sollievo della Sofferenza IRCCS | 1 |
| Danish Multiple Sclerosis Hospitals | 1 |
| Sundance Biosciences, Inc. | 1 |
| NYU Langone Health | 1 |
| Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. | 1 |
| University of Pennsylvania | 1 |
| Huashan Hospital | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| Queen Mary University of London | 1 |
| Sichuan Academy of Medical Sciences | 1 |
| Holland Bloorview Kids Rehabilitation Hospital | 1 |
| University of Zurich | 1 |
| Washington University School of Medicine | 1 |
| Clinical Academic Center (2CA-Braga) | 1 |
| University Hospital, Antwerp | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| Canada | 7 |
| Italy | 5 |
| Poland | 4 |
| Australia | 3 |
| Germany | 3 |
| Spain | 3 |
| Czechia | 3 |
| Denmark | 3 |
| China | 3 |
| Belgium | 2 |
| France | 2 |
| Ireland | 2 |
| Netherlands | 2 |
| Serbia | 2 |
| Israel | 2 |
| United Kingdom | 2 |
| Portugal | 2 |
| Sweden | 1 |
| Bosnia and Herzegovina | 1 |
| Georgia | 1 |
| North Macedonia | 1 |
| Ukraine | 1 |
| Puerto Rico | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private investigators in the United States](https://specstream.ai/data/businesses/private-investigators/united-states)
- [Medical schools in the United States](https://specstream.ai/data/businesses/medical-schools/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
- [Educational research institutes in the United States](https://specstream.ai/data/businesses/educational-research-institutes/united-states)
- [Business management services in the United States](https://specstream.ai/data/businesses/business-management-services/united-states)
- [Aluminum suppliers in the United States](https://specstream.ai/data/businesses/aluminum-suppliers/united-states)
